Skip to Content

VPRIV Approval History

  • FDA approved: Yes (First approved February 26th, 2010)
  • Brand name: VPRIV
  • Generic name: velaglucerase alfa
  • Dosage form: for Injection
  • Company: Shire plc
  • Treatment for: Gaucher Disease

VPRIV (velaglucerase alfa) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with Type 1 Gaucher disease.

Development History and FDA Approval Process for VPRIV

DateArticle
Feb 26, 2010Approval FDA Approves VPRIV to Treat Gaucher Disease
Nov  4, 2009FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease
Sep  2, 2009Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
Jul  7, 2009Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide